Actos 15 mg tablets, AVELUMAB clinical trials

CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITHOUT ACHIEVING A DEEP MOLECULAR RESPONSE: AN ADAPTIVE TRIAL BASED ON A DROP LOSER DESIGN - ACTIW STUDY

This study looks at new drug combinations for people with Chronic Myeloid Leukaemia (CML) who haven't achieved a very low level of the disease. It aims to see if these new treatments can help more people reach deeper remission and potentially stop treatment later on.